Powered by

Roche's Tecentriq Plus Platinum-Based Chemotherapy Reduced Risk of Disease Worsening or Death

Aug 05, 2019 - Targeted News Service

Roche, a biotech company, issued the following news release:

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMvigor130 study met its co-primary endpoint of investigator-assessed progression-free survival (PFS). The combination of Tecentriq(R) (atezolizumab) plus platinum-based chemotherapy showed a statistically significant reduction in the risk of disease worsening or death (PFS) in people with previously untreated locally advanced or metastatic urothelial carcinoma...